Drug Trial Radar · NCT01430442
Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine
Last checked: Nov 19, 2026Latest source record: Feb 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,026
Actual
Start
Oct 2011
Primary completion
May 2012
Study completion May 2012
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 8, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of rimegepant (BMS-927711) compared with placebo in the acute treatment of migraine as measured by Pain Freedom (headache pain intensity level reported as "no pain") at 2 hours post dose using a four point numeric rating scale (no pain, mild pain, moderate pain, severe pain) while identifying an optimal dose to support the Phase 3 clinical trials.
Conditions
- Migraine
- Acute Treatment of Migraine
Interventions
RimegepantDrug
Rimegepant capsules
PlaceboDrug
Rimegepant placebo-matching capsules
SumatriptanDrug
Rimegepant matching sumatriptan and Rimegepant matching placebo capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Pain Free Participants (Pain Freedom) at 2 Hours Post-doseTime frame: Baseline, 2 hours post-dose
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Scottsdale, Arizona
Clinical Res. Advantage Inc/ Desert Clinical Research Llc
Tempe, Arizona
University Of California, San Francisco
San Francisco, California
California Medical Clinic For Headache
Santa Monica, California
Encompass Clinical Research
Spring Valley, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Radiant Research, Inc.
Denver, Colorado
Miami Research Associates
Miami, Florida
Renstar Medical Research
Ocala, Florida
Compass Research, Llc
Orlando, Florida
Broward Research Group
Pembroke Pines, Florida
Comprehensive Clinical Development, Inc
St. Petersburg, Florida
Diamond Headache Clinic, Ltd.
Chicago, Illinois
Milford Emergency Associates, Inc.
Milford, Massachusetts
Medvadis Research Corporation
Watertown, Massachusetts
Michigan Head Pain And Neurological Institute
Ann Arbor, Michigan
Clinical Research Institute, Inc.
Minneapolis, Minnesota
The Center For Pharmaceutical Research. Pc
Kansas City, Missouri
Clinvest/ A Division Of Banyan Group, Inc.
Springfield, Missouri
Mercy Health Research
St Louis, Missouri
Regional Clinical Research Inc.
Endwell, New York
Central New York Clinical Research
Manlius, New York
Rochester Clinical Research, Inc.
Rochester, New York
Pharmquest
Greensboro, North Carolina
Wake Research Associates
Raleigh, North Carolina
Pmg Research Of Winston-Salem
Winston-Salem, North Carolina
Community Research
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
Clinical Research Of Philadelphia, Llc
Philadelphia, Pennsylvania
Omega Medical Research
Warwick, Rhode Island
Coastal Carolina Research Center, Inc.
Mt. Pleasant, South Carolina
Clinsearch, Llc
Chattanooga, Tennessee
Premier Research Group Limited
Austin, Texas
Futuresearch Trials Of Neurology
Austin, Texas
R/D Clinical Research, Inc.
Lake Jackson, Texas
J. Lewis Research, Inc
Salt Lake City, Utah
J. Lewis Research, Inc
Salt Lake City, Utah
The Innovative Clinical Research Center
Alexandria, Virginia
Tidewater Integrated Medical Research
Virginia Beach, Virginia
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.